Science Pool

Evotec

Recent Posts

Shining a Spotlight on the Mighty Mitochondria

Posted by Evotec on Sep 18, 2023 10:00:00 AM

This week we celebrate Mitochondrial Awareness Week, a dedicated time to turn our attention to these tiny yet incredibly powerful cellular structures that play a pivotal role in our health and well-being. While the mention of mitochondria might not immediately conjure up images of groundbreaking scientific discoveries, these dynamic organelles deserve a moment in the spotlight. They are the unsung heroes of our cells, and their importance extends far beyond just being the "powerhouses" that produce cellular energy.

In addition to being cellular “powerhouses” and generating the majority of a cells energy in the form of adenosine triphosphate (ATP), mitochondria are also involvement in apoptosis, calcium signalling, regulation of cellular metabolism and proliferation of haem and steroids.

Unfortunately, mitochondria are also a common target for drug-induced toxicity which can have a significant adverse effect on cellular function and overall health. Here are some key reasons why understanding the potential for mitochondrial toxicity is crucial when screening for a drug candidate:

  1. Energy Production: Any disruption in mitochondrial function can lead to a decrease in ATP production, which can have detrimental effects on cellular processes and overall cellular health.
  2. Cellular Health: Healthy mitochondria are essential for the proper functioning of cells and tissues. Mitochondrial dysfunction can lead to a range of health issues, including neurodegenerative diseases, cardiovascular diseases, and metabolic disorders.
  3. Potential Adverse Effects: Drugs that cause mitochondrial toxicity can lead to serious adverse effects in patients. For example, some drugs have been associated with muscle weakness, neuropathy, or liver damage due to their impact on mitochondria. Identifying mitochondrial toxicity during drug screening can help prevent these adverse effects in clinical trials and post-market use.
  4. Mitochondrial DNA Damage: Mitochondria have their own DNA (mtDNA), and they replicate independently of the cell nucleus. Drug-induced mitochondrial toxicity can result in mtDNA damage, mutations, or deletions. This can further impair mitochondrial function and contribute to a variety of diseases.
  5. Drug Efficacy: In addition to avoiding harm to mitochondria, it's important to consider the potential benefits of a drug on mitochondrial function. Some drug candidates may enhance mitochondrial function, which can be beneficial for diseases characterized by mitochondrial dysfunction, such as certain neurodegenerative disorders.
  6. Predictive Toxicology: Early identification of mitochondrial toxicity can help pharmaceutical companies make informed decisions about whether to advance a drug candidate in the development pipeline. Identifying mitochondrial toxicity in the preclinical stages allows for the modification of compounds or the discontinuation of those with high toxicity, potentially saving time and resources.
  7. Regulatory Requirements: Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), require thorough safety assessments, including an evaluation of mitochondrial toxicity, during the drug development process. Failing to address mitochondrial toxicity issues can result in regulatory delays or rejection of a drug candidate.

In summary, studying mitochondrial toxicity is essential to ensure the safety and efficacy of drug candidates. It helps prevent potential harm to patients, reduces the risk of adverse effects, and supports the development of drugs that are not only effective but also safe for long-term use.

Cyprotex offer a number of approaches to study mitochondrial toxicity, including:

In addition, we frequently publish our work in the field of understanding mitochondrial toxicity. You may be interested in:

Poster: A Comprehensive Approach using In Vitro Assays to Detect and Identify Mechanism of Mitochondrial Toxicity

Publication: A Combined In Vitro Approach to Improve the Prediction of Mitochondrial Toxicants

Contact us to find out more about our mitochondrial toxicity services today!

 

Tags: Blog, ADME/DMPK

BIO-EUROPE 2023

Posted by Evotec on Sep 12, 2023 3:52:32 PM

Date: November 6 - 8

Location: Munich, Germany

 

BIO-Europe-f01c223ebce338c77f16ac67cabeb94b

 

Our team at Bio-Europe

  • Bernd Muehlenweg, SVP, Innovate Strategic Initiatives
  • Christelle Dagoneau, SVP, Business Development Europe, Just – Evotec Biologics
  • Christian Buhlmann, EVP, Head of Global BD Development
  • Florence Eustache, VP, Business Development • Global BD Discovery
  • Hannah Seitz • Global BD Missions
  • Insa Hartmann, Associate, Innovate Strategic Initiatives • Global BD Missions
  • Irving Donadon, Business Development Manager
  • Jason Brown, SVP, Business Development
  • Ryan Brady, EVP, Head of Business Development, Global BD Discovery
  • Thomas Hanke, EVP, Head of Academic Partnerships • Corporate Management
  • Victor Lopez, Senior Director, Innovate Partnering & Licensing • Global BD Missions

 

Evotec is a platinum sponsor at Bio-Europe and will be exhibiting at booth #81

Our experts will be speaking at Bio-Europe, details will be available shortly.

 

Learn more about Bio-Europe 2023

Tags: Events, Evotec

CPhI Barcelona 2023

Posted by Evotec on Sep 12, 2023 2:28:34 PM

Date: 24th - 26th October 2023

Location: Fira Barcelona Gran Via, Spain

Our team at CPhI Barcelona

  • Christian Buhlmann, EVP, Head of Global BD Development 
  • David Straight, Director of Business Development • US Business Development
  • Harald Zimmer, Director of Business Development Evotec DS Germany
  • Jeffrey Naroian, Senior Vice President US Business Development 
  • Lynsey Haskayne, Senior Director • Business Development Europe
  • Margit Wissenbach, VP Business Development • Business Development Europe
  • Nigel Shipston, Senior Director, Business Development Global Biologics 
  • Claudio Cafiero, Senior Manager • Pharmaceutical Development & Manufacturing
  • Elisabetta Verardo, EVP Head of Global Drug Development Quality Unit and Site Head Modena • Global Drug Development
  • Emanuela Del Vesco, SVP Pharmaceutical Development & Manufacturing • Global Drug Development 
  • Jerome Dauvergne, EVP, Head of Global API Chemistry, Process Development & Manufacturing - Managing Director, Evotec DS Germany
  • Paola Tocchetti, SVP Head of Global Regulatory Affairs • Quality Unit Verona
  • Paolo Gatti, SVP Pharmaceutical Development - Scientific Direction • Global Drug Development
  • Philip Patrick Boehme, EVP, Head of Partnering and Transformation • Just - Evotec Biologics
  • Nerina Coppini, Senior Marketing Manager, Strategic Marketing  
  • Sara Trevisan, Senior Category Buyer API • Global Category Buyer API
      

Evotec will be exhibiting at booth #3R81

 

Our fully integrated solutions

Our CMC solutions are enhanced by the seamless integration of expertise and capabilities spanning from target identification to clinical development, including early and regulated ADME-Tox and safety pharmacology, regulatory support, clinical development & translational medicine:

  • Drug Substance & Drug Product Development from Lab Scale to Commercial Manufacturing
  • GMP Manufacturing of Small Molecules, Biologics, Cell Therapy Products
  • Early and Regulated ADME-Tox and Safety Pharmacology
  • Full Regulatory Support, Clinical Development & Translational Medicine (Phase 1/1b)

Meet us at booth #3R81

 

Learn more about Evotec at CPhI Barcelona and AAPS PharmSci360 2023

Tags: Events, Evotec

AAPS PharmSci360 2023

Posted by Evotec on Sep 12, 2023 12:48:56 PM

Date: 22nd - 25th October 2023

Location: Orange County Convention Center - Orlando, FL

Orlando_AdobeStock_617622107_rsz-1

Our team at AAPS PharmSci360

  • Claudio Marcello Marzo, Associate Scientist • In Vivo Safety
  • Pascale Clement, VP Pharmaceutical Development Science & Strategy • Pharmaceutical Development & Manufacturing
  • Piero Piccinni, Senior Supervisor • Drug Product Manufacturing Operations
  • Dhimant Patel, Senior Director • Business Development
  • Michael Campognone, Senior Director • Business Development

Evotec will be exhibiting at booth #2935


View our AAPS PharmSci360 scientific presentations. Request your personal copy!

You will receive our four posters and two Rapid Fire presentations in your inbox right after the event. 

Our fully integrated solutions

Our CMC solutions are enhanced by the seamless integration of expertise and capabilities spanning from target identification to clinical development, including early and regulated ADME-Tox and safety pharmacology, regulatory support, clinical development & translational medicine:

  • Drug Substance & Drug Product Development from Lab Scale to Commercial Manufacturing
  • GMP Manufacturing of Small Molecules, Biologics, Cell Therapy Products
  • Early and Regulated ADME-Tox and Safety Pharmacology
  • Full Regulatory Support, Clinical Development & Translational Medicine (Phase 1/1b)

Meet us at booth #2935

 

Learn more about Evotec at CPhI Barcelona and AAPS PharmSci360 2023

Tags: Events, Evotec

iPSC-Derived Cell Therapies Summit 2023

Posted by Evotec on Sep 12, 2023 11:35:30 AM

Date: 3rd - 4th October 2023

Location: Boston, MA, United States

Attending: Audrey Holtzinger, Vice President iPSC Cell Therapy, and Olivia Candini, Cell Therapy Process Development Supervisor

Evotec is Innovation Partner at this event. 

 

Oral and poster presentation

 

Diabetes cell therapy with Evotec iPSC-derived islet-like clusters in the Sernova Cell PouchTM

Presented by Audrey Holtzinger, Vice President iPSC Cell Therapy, Evotec

  • Update on Evotec’s end-to-end integrated platform for iPSC-based cell therapeutics
  • Results from pre-clinical testing of iPSC-derived islet-like clusters combined with the implantable Cell Pouch
Oral presentation date and time: October 4th, 2023, 2:30pm local

Session: The Future is iPSCs: Re-Evaluating Translational & Strategical Priorities to Drive Next Steps Across the iPSC Industry

 

Development of an off-the-shelf allogenic anti-cancer cell therapy using potent iPSC-derived natural killer cells

Presented by Audrey Holtzinger, Vice President iPSC Cell Therapy, Evotec

Poster presentation date and time: October 3rd, 2023, 3:00pm local

 

 

Learn more about the iPSC-Derived Cell Therapies Summit 2023

Tags: Events, Evotec

How an Integrated, Continuous, Intensified Approach for Manufacturing Biologics Provides Productivity and Quality Benefits

Posted by Evotec on Aug 29, 2023 6:31:11 PM

Tags: Articles & Whitepapers, Biologics

Why early mAb Sequence Optimization can Improve Developability and Reduce Costs

Posted by Evotec on Aug 29, 2023 6:27:55 PM

Tags: Articles & Whitepapers, Biologics

Reducing biopharmaceutical manufacturing costs through continuous processing

Posted by Evotec on Aug 29, 2023 6:17:11 PM

We recently published our latest paper in Drug Discovery Today. Our authors Fernando Garcia and Eva Gefroh introduce a type of flexible biomanufacturing facility called J.POD®, capable of capitalizing on Intensified Continuous Biomanufacturing (ICB) to deliver against current cost and speed needs in the biopharmaceutical industry. We are pleased to share this featured review with industry and partners as we continue to work together to expand access to medicines that matter.

Abstract

In this work, process models were developed to capture the impact of biomanufacturing costs on a commercial scale and emphasize the way in which facility design and operation must balance meeting product demand while minimizing production costs. Using a scenario-based modeling approach, several facility design strategies were evaluated, including a traditional large stainless-steel facility and a small footprint, portable-on-demand (POD)-based facility. Bioprocessing platforms were compared by estimating their total production costs across different facility types and specifically illustrating how continuous bioprocessing has gained in popularity as a novel and cost-effective approach to manufacture high-quality biopharmaceuticals. The analysis showed how fluctuations in market demand have a dramatic effect on manufacturing costs and plant utilization, with far-reaching implications on the total cost to patients. Read the full article in Drug Discovery Today.

READ NOW

Tags: Articles & Whitepapers, Biologics

Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances anti-tumour immunity

Posted by Evotec on Aug 29, 2023 8:52:27 AM

A major disadvantage in fighting cancer is the low immunogenicity of cancer cells, impairing body’s ability to identify and destroy them. This paper describes STM3006, a novel, chemically distinct inhibitor of METTL3 with improved biochemical and cellular potency compared to the previously published ligand STM2457. Crystallography revealed improved binding within a newly formed ligand-induced lipophilic pocket within the protein, while retaining the interactions that provide high selectivity over other methyltransferases.

The authors demonstrated that METTL3 inhibition with STM3006 stimulates a cell-intrinsic interferon response through double-stranded RNA formation. This immunomodulatory mechanism is distinct from current immunotherapeutic agents and provides the molecular rationale for combination with anti-PD1 immune checkpoint blockade to augment anti-tumour immunity. In combination these therapies have demonstrated the ability to overcome malignant clones insensitive to the single agents. 

This article is written in collaboration with Storm Therapeutics.

READ NOW

Tags: Articles & Whitepapers

57th Congress of the European Societies of Toxicology - EuroTox

Posted by Evotec on Aug 24, 2023 1:49:27 PM

Date: 10th -13th September 2023

Location: GR - Ljubljana Exhibition and Convention Centre, Ljubljana Slovenia

Booth Location: 59

Attending: Ben Park, Alessandro Casartelli, Oksana Nikolayenko, Daniel Gliesche, Martin Augustin, Giuseppe D'Angelo & Rob Brown

Presentations

“Genotoxicity Risk Assessment during Lead Optimization Phase in Pharmaceutical Drug Development” - Presented by Alessandro Casartelli 

"Detection of Chemical Reactive Metabolites in a Glutathione depleted in vitro system" - Presented by Ben Park 

Download: Bioactivation Driven Toxicity Product Sheet

Learn more about EuroTox 2023

Tags: Events, Evotec, Cyprotex